The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Global Anti-VEGF market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Anti-VEGF market research.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Anti-VEGF market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Amgen Inc.
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Xbrane Biopharma AB
Allergan, Bayer AG
Regeneron Pharmaceuticals Inc.
Viatris Inc. (Mylan)
Segment by Type
Avastin
Lucentis
Eylea
Segment by Application
Macular Edema
Diabetic Retinopathy
Retinal Vein Occlusion
Age-Related Macular Degeneration
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Anti-VEGF report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Global Anti-VEGF market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Anti-VEGF market research.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Anti-VEGF market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Amgen Inc.
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Xbrane Biopharma AB
Allergan, Bayer AG
Regeneron Pharmaceuticals Inc.
Viatris Inc. (Mylan)
Segment by Type
Avastin
Lucentis
Eylea
Segment by Application
Macular Edema
Diabetic Retinopathy
Retinal Vein Occlusion
Age-Related Macular Degeneration
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Anti-VEGF report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Anti-VEGF Market Overview
1.1 Product Overview and Scope of Anti-VEGF
1.2 Anti-VEGF Segment by Type
1.2.1 Global Anti-VEGF Market Value Comparison by Type (2023-2029)
1.2.2 Avastin
1.2.3 Lucentis
1.2.4 Eylea
1.3 Anti-VEGF Segment by Application
1.3.1 Global Anti-VEGF Market Value by Application: (2023-2029)
1.3.2 Macular Edema
1.3.3 Diabetic Retinopathy
1.3.4 Retinal Vein Occlusion
1.3.5 Age-Related Macular Degeneration
1.4 Global Anti-VEGF Market Size Estimates and Forecasts
1.4.1 Global Anti-VEGF Revenue 2018-2029
1.4.2 Global Anti-VEGF Sales 2018-2029
1.4.3 Global Anti-VEGF Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Anti-VEGF Market Competition by Manufacturers
2.1 Global Anti-VEGF Sales Market Share by Manufacturers (2018-2023)
2.2 Global Anti-VEGF Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Anti-VEGF Average Price by Manufacturers (2018-2023)
2.4 Global Anti-VEGF Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Anti-VEGF, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-VEGF, Product Type & Application
2.7 Anti-VEGF Market Competitive Situation and Trends
2.7.1 Anti-VEGF Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-VEGF Players Market Share by Revenue
2.7.3 Global Anti-VEGF Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-VEGF Retrospective Market Scenario by Region
3.1 Global Anti-VEGF Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Anti-VEGF Global Anti-VEGF Sales by Region: 2018-2029
3.2.1 Global Anti-VEGF Sales by Region: 2018-2023
3.2.2 Global Anti-VEGF Sales by Region: 2024-2029
3.3 Global Anti-VEGF Global Anti-VEGF Revenue by Region: 2018-2029
3.3.1 Global Anti-VEGF Revenue by Region: 2018-2023
3.3.2 Global Anti-VEGF Revenue by Region: 2024-2029
3.4 North America Anti-VEGF Market Facts & Figures by Country
3.4.1 North America Anti-VEGF Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Anti-VEGF Sales by Country (2018-2029)
3.4.3 North America Anti-VEGF Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-VEGF Market Facts & Figures by Country
3.5.1 Europe Anti-VEGF Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Anti-VEGF Sales by Country (2018-2029)
3.5.3 Europe Anti-VEGF Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-VEGF Market Facts & Figures by Country
3.6.1 Asia Pacific Anti-VEGF Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Anti-VEGF Sales by Country (2018-2029)
3.6.3 Asia Pacific Anti-VEGF Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Anti-VEGF Market Facts & Figures by Country
3.7.1 Latin America Anti-VEGF Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Anti-VEGF Sales by Country (2018-2029)
3.7.3 Latin America Anti-VEGF Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Anti-VEGF Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-VEGF Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Anti-VEGF Sales by Country (2018-2029)
3.8.3 Middle East and Africa Anti-VEGF Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-VEGF Sales by Type (2018-2029)
4.1.1 Global Anti-VEGF Sales by Type (2018-2023)
4.1.2 Global Anti-VEGF Sales by Type (2024-2029)
4.1.3 Global Anti-VEGF Sales Market Share by Type (2018-2029)
4.2 Global Anti-VEGF Revenue by Type (2018-2029)
4.2.1 Global Anti-VEGF Revenue by Type (2018-2023)
4.2.2 Global Anti-VEGF Revenue by Type (2024-2029)
4.2.3 Global Anti-VEGF Revenue Market Share by Type (2018-2029)
4.3 Global Anti-VEGF Price by Type (2018-2029)
5 Segment by Application
5.1 Global Anti-VEGF Sales by Application (2018-2029)
5.1.1 Global Anti-VEGF Sales by Application (2018-2023)
5.1.2 Global Anti-VEGF Sales by Application (2024-2029)
5.1.3 Global Anti-VEGF Sales Market Share by Application (2018-2029)
5.2 Global Anti-VEGF Revenue by Application (2018-2029)
5.2.1 Global Anti-VEGF Revenue by Application (2018-2023)
5.2.2 Global Anti-VEGF Revenue by Application (2024-2029)
5.2.3 Global Anti-VEGF Revenue Market Share by Application (2018-2029)
5.3 Global Anti-VEGF Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Amgen Inc.
6.1.1 Amgen Inc. Corporation Information
6.1.2 Amgen Inc. Description and Business Overview
6.1.3 Amgen Inc. Anti-VEGF Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Amgen Inc. Anti-VEGF Product Portfolio
6.1.5 Amgen Inc. Recent Developments/Updates
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 F. Hoffmann-La Roche Ltd. Corporation Information
6.2.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
6.2.3 F. Hoffmann-La Roche Ltd. Anti-VEGF Sales, Revenue and Gross Margin (2018-2023)
6.2.4 F. Hoffmann-La Roche Ltd. Anti-VEGF Product Portfolio
6.2.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
6.3 Pfizer, Inc.
6.3.1 Pfizer, Inc. Corporation Information
6.3.2 Pfizer, Inc. Description and Business Overview
6.3.3 Pfizer, Inc. Anti-VEGF Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Pfizer, Inc. Anti-VEGF Product Portfolio
6.3.5 Pfizer, Inc. Recent Developments/Updates
6.4 Xbrane Biopharma AB
6.4.1 Xbrane Biopharma AB Corporation Information
6.4.2 Xbrane Biopharma AB Description and Business Overview
6.4.3 Xbrane Biopharma AB Anti-VEGF Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Xbrane Biopharma AB Anti-VEGF Product Portfolio
6.4.5 Xbrane Biopharma AB Recent Developments/Updates
6.5 Allergan, Bayer AG
6.5.1 Allergan, Bayer AG Corporation Information
6.5.2 Allergan, Bayer AG Description and Business Overview
6.5.3 Allergan, Bayer AG Anti-VEGF Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Allergan, Bayer AG Anti-VEGF Product Portfolio
6.5.5 Allergan, Bayer AG Recent Developments/Updates
6.6 Regeneron Pharmaceuticals Inc.
6.6.1 Regeneron Pharmaceuticals Inc. Corporation Information
6.6.2 Regeneron Pharmaceuticals Inc. Description and Business Overview
6.6.3 Regeneron Pharmaceuticals Inc. Anti-VEGF Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Regeneron Pharmaceuticals Inc. Anti-VEGF Product Portfolio
6.6.5 Regeneron Pharmaceuticals Inc. Recent Developments/Updates
6.7 Viatris Inc. (Mylan)
6.6.1 Viatris Inc. (Mylan) Corporation Information
6.6.2 Viatris Inc. (Mylan) Description and Business Overview
6.6.3 Viatris Inc. (Mylan) Anti-VEGF Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Viatris Inc. (Mylan) Anti-VEGF Product Portfolio
6.7.5 Viatris Inc. (Mylan) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-VEGF Industry Chain Analysis
7.2 Anti-VEGF Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-VEGF Production Mode & Process
7.4 Anti-VEGF Sales and Marketing
7.4.1 Anti-VEGF Sales Channels
7.4.2 Anti-VEGF Distributors
7.5 Anti-VEGF Customers
8 Anti-VEGF Market Dynamics
8.1 Anti-VEGF Industry Trends
8.2 Anti-VEGF Market Drivers
8.3 Anti-VEGF Market Challenges
8.4 Anti-VEGF Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
